For example, blocking the CXCR2 receptor, which is involved in attracting MDSCs to the tumor location, has been demonstrated to enhance the efficacy of anti-PD-1 therapy in preclinical models of melanoma [90]. This evidence concerns the gene PDCD1 and neoplasm.